News & Updates

Show Multimedia Only

RT-based attention bias modification helps prevent PTSD in soldiers

21 Mar 2026 by

The use of response time (RT)-based attention bias modification (ABM) can protect soldiers against the development of post-traumatic stress disorder (PTSD) when implemented before exposure to combat, suggests a study.

RT-based attention bias modification helps prevent PTSD in soldiers

21 Mar 2026

Malignant disease may re-emerge following SOT among cancer survivors

21 Mar 2026

Solid organ transplant (SOT) recipients with a history of cancer are at increased risk of post-transplant cancer, especially the same type of cancer, according to a study.

Malignant disease may re-emerge following SOT among cancer survivors

21 Mar 2026

VA device a valuable add-on to diabetes self-care regimens

21 Mar 2026 by

A smart speaker appears to have gone beyond its initial capabilities, improving mental health and diabetes-related outcomes in older adults with type 2 diabetes (T2D) in the Brazilian IVAM-ED* trial.

VA device a valuable add-on to diabetes self-care regimens

21 Mar 2026

Improving breast cancer survivorship as part of care continuum can reduce recurrence risk

21 Mar 2026 by

Journeying with breast cancer (BC) survivors through holistic multidisciplinary care enables them to cope better with physical and emotional stress, improves survivorship and adherence to endocrine therapy, and reduces recurrence risk, emphasized BC coach, Ms Isabel Galiano, and a multidisciplinary oncology care panel at the 14^th Asia-Pacific Breast Cancer Summit (APBCS 2026).

Improving breast cancer survivorship as part of care continuum can reduce recurrence risk

21 Mar 2026

Non-INSTI-based ART combination on the horizon for broad HIV population

20 Mar 2026 by

The investigational combination of doravirine plus islatravir (DOR/ISL)—a fixed-dose, once-daily oral antiretroviral therapy (ART) regimen that does not rely on integrase strand-transfer inhibitors (INSTIs)—is shaping up to be a promising alternative in the management of HIV, showing noninferiority to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in individuals initiating treatment for the first time and maintaining virologic suppression in those switching from various ART regimens, as shown in three phase III studies presented at CROI 2026.

Non-INSTI-based ART combination on the horizon for broad HIV population

20 Mar 2026

Xanomeline-trospium chloride combo safe, effective in schizophrenia

20 Mar 2026

Treatment with xanomeline and trospium chloride (X/T) over 52 weeks appears safe and well tolerated, demonstrating durable symptom improvements in individuals with schizophrenia, reports a study.

Xanomeline-trospium chloride combo safe, effective in schizophrenia

20 Mar 2026

How effective are COVID-19 mRNA vaccines in children?

20 Mar 2026 by

Immunization with COVID-19 mRNA vaccines is safe and provides a small protective benefit in children aged 6‒17 years, as shown in a Spain study.

How effective are COVID-19 mRNA vaccines in children?

20 Mar 2026

MeDi-DASH-CHH diet improves lipid profiles, eating patterns in older adults with dyslipidaemia

20 Mar 2026

The combination of the Mediterranean diet, DASH diet, and the Chinese Healthy Heart (Medi-DASH-CHH) dietary pattern results in improvements in lipid profiles and even encourages healthful eating behaviours among older adults with dyslipidaemia, a recent study has shown.

MeDi-DASH-CHH diet improves lipid profiles, eating patterns in older adults with dyslipidaemia

20 Mar 2026

Meta-analysis supports use of dupilumab in first-line treatment of prurigo nodularis

20 Mar 2026

In patients with prurigo nodularis, treatment with dupilumab provides consistent, meaningful improvements in pruritus while having a favourable safety profile, according to a meta-analysis.

Meta-analysis supports use of dupilumab in first-line treatment of prurigo nodularis

20 Mar 2026

Novel single-tablet BIC/LEN noninferior to standard of care in PWH

20 Mar 2026 by

A single-tablet regimen (STR) combining bictegravir and lenacapavir (BIC/LEN) was noninferior to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in maintaining virologic suppression among people with HIV (PWH) who are virologically suppressed, according to the ARTISTRY-2 trial presented at CROI 2026.

Novel single-tablet BIC/LEN noninferior to standard of care in PWH

20 Mar 2026

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

RT-based attention bias modification helps prevent PTSD in soldiers

RT-based attention bias modification helps prevent PTSD in soldiers

Malignant disease may re-emerge following SOT among cancer survivors

Malignant disease may re-emerge following SOT among cancer survivors

VA device a valuable add-on to diabetes self-care regimens

VA device a valuable add-on to diabetes self-care regimens

Improving breast cancer survivorship as part of care continuum can reduce recurrence risk

Improving breast cancer survivorship as part of care continuum can reduce recurrence risk

Non-INSTI-based ART combination on the horizon for broad HIV population

Non-INSTI-based ART combination on the horizon for broad HIV population

Xanomeline-trospium chloride combo safe, effective in schizophrenia

Xanomeline-trospium chloride combo safe, effective in schizophrenia

How effective are COVID-19 mRNA vaccines in children?

How effective are COVID-19 mRNA vaccines in children?

MeDi-DASH-CHH diet improves lipid profiles, eating patterns in older adults with dyslipidaemia

MeDi-DASH-CHH diet improves lipid profiles, eating patterns in older adults with dyslipidaemia

Meta-analysis supports use of dupilumab in first-line treatment of prurigo nodularis

Meta-analysis supports use of dupilumab in first-line treatment of prurigo nodularis

Novel single-tablet BIC/LEN noninferior to standard of care in PWH

Novel single-tablet BIC/LEN noninferior to standard of care in PWH